) is an antidepressant of the serotonin antagonist and reuptake inhibitor (SARI) class. Trazodone also has anti-anxiety (anxiolytic) and sleep-inducing (hypnotic) effects. Antidepressant medications are used to treat a variety of conditions, including depression and other mental/mood disorders. The following information is NOT intended to endorse drugs or recommend therapy.
Desyrel trazodone insomni
Trazodone (Desyrel) is classified as an atypical antidepressant, functioning specifiy as an SARI (serotonin antagonist and reuptake inhibitor). Trazodone, a phenylpiperazine–triazolopyridine antidepressant, was orinally discovered and developed in Italy in the 1960s by Angelini research laboratories.
This agent was developed according to the mental pain hypothesis, which was postulated from studying patients and which proposes that depression is associated with a decreased pain threshold .
Desyrel trazodone insomni
Desyrel trazodone insomni
Trazodone is an antidepressant drug that's prescribed to treat the symptoms of depression. Trazodone is used to treat depression and to treat the combination of symptoms of anxiety and depression.
MAO inhibitors: Do not administer trazodone within 14 days of administering a MAO inhibitor when treating a psychiatric disorder Coadministration with MAO inhibitors linezolid or IV methylene blue: Trazodone not recommended in patients actively receiving linezolid or IV methylene blue; consider other interventions if treating psychiatric condition; if coadministration necessary, because benefits outweh risks, monitor for serotonin syndrome for 2 weeks or until 24 hr after last dose of linezolid or IV methylene blue, whichever comes first; may resume trazodone 24 hr after last dose of linezolid or IV methylene blue Immediate release: 25-50 mg PO q HS; increase dose by 25-50 mg every three days if inpatient or every week if oupatient not to exceed 75-150 mg/day Extended release: Experience limited; use 150 mg PO HS initially; may increase by increments of 75 mg/day q3Days; not to exceed 375 mg/day 65 years In children and young adults, risks must be wehed against the benefits of taking antidepressants Patients should be monitored closely for changes in behavior, clinical worsening, and suicidal tendencies; this should be done during initial 1-2 months of therapy and dosage adjustments The patient’s family should communicate any abrupt changes in behavior to the healthcare provider Worsening behavior and suicidal tendencies that are not part of the presenting symptoms may require discontinuation of therapy This drug is not FDA approved for use in pediatric patients or for treatment of bipolar depression Administer shortly after meal; if drowsiness occurs, decrease dosage or give most of divided dosage HS Discontinue if prolonged or inappropriate erection occurs Discontinue if neutropenia, leukopenia Use caution in patients with risk of seizures Clinical worsening and suicide ideation may occur despite medication in adolescents and young adults (18-24 years) Perform leukocyte and differential with fever, sore throat, or other sns of infection Discontinue if leukocytes/ANC decreases below normal range Coadministration with MAO inhibitors: risk of serotonin syndrome Drugs that interfere with serotonin reuptake have been associated with bleeding; trazodone may also impair platelet aggregation resulting in increased risk of bleeding events Potentially life-threatening serotonin syndrome reported when coadministered with drugs that impair serotonin metabolism (in particular, MAOIs, including nonpsychiatric MAOIs, such as linezolid and IV methylene blue) (see Contraindications) Coadministration with NSAIDs and aspirin, may increase risk of bleeding Bone fractures associated with antidepressant treatments Increases risk of hyponatremia Use caution in patients with risk of seizures including head trauma, alcoholism, brain damage May worsen psychosis in patients or precipitate mania or hypomania; screen, for bipolar disorder, patients presenting with depressive symptoms May cause orthostatic hypotension and syncope; use wiht caution QT prolongation with or without torsade de pointes and ventricular tachycardia reported May increase risk associated with electroconvulsive therapy (ECT); discontinue ECT before initiating trazodone therapy Risk of mydriasis; may trger angle closure attack in patients with angle closure glaucoma with anatomiy narrow angles without a patent iridectomy Antidepressant structurally unrelated to SSRIs, tricyclics, tetracyclics or MAOIs, but also inhibits neuronal uptake of serotonin (but not NE); it is a histamine and alpha1-adrenergic receptor antagonist; causes adrenoceptor subsensitivity Almost completely absorbed (increased by food) Onset: 6 weeks (antidepressant); 1-3 hr sleep aid Peak serum time: 30-100 min (up to 2.5 hr if taken with food); 9 hr (extended release) Concentration: 480-1620 ng/m L (dose-dependent) The above information is provided for general informational and educational purposes only. ZOVIRAX POISON DOGSA
Desyrel trazodone insomni:
Rating: 90 / 100
Overall: 98 Rates